confidential treatment requested redacted portions are indicated by [ * * * * ] term sheet for license agreement ( term sheet ) this term sheet is not a binding contract between the parties, but it shall be kept confidential. the term sheet is the initial basis for an offer to license the intellectual property rights specified below, and sets forth the primary licensing terms as agreed upon by the undersigned parties, to be codified in a license agreement which is to be negotiated in full between the parties. subject terms licensor inven2 as ( lnven2 ) on behalf of the university of oslo ( uio ) and oslo university hospital hf ( ous ) licensee atossa genetics, inc contact name ( s ) and information steven quay, ceo and president, atossa genetics, inc. 4105 e madison st, suite 320, seattle, wa 98112 t : 206 # # # - # # # - # # # #. object of license ipr including know how related to dofi b - 11035 " combining gene signatures improves prediction of breast cancer survival " as well as patent / patent application ( s ) to be filed to protect this ipr. ownership to patent application ( s ) to be licensed uio / ous. inven2 is empowered to administer uio's / ous'intellectual property rights, including entering into license agreements patent filing, prosecution and defense at national / regional filing, inven2 will file the patent application in the following countries : usa. licensee may ask inven2 to file in additional countries regions at licensee's cost. licensee may choose to exclude certain countries from the license agreement. patent defense : licensee has first right but no obligation. inven2 gets the right to defend the patent rights if licensee does not exercise its first right. publication licensor has the right to publish, and use in teaching and for research purposes, the research results covered in the license agreement type of license granted exclusive geographical scope for license worldwide right to transfer entire license agreement yes. field of use breast cancer and precancerous breast lesions. responsible for product development, introduction on the market, advertisement licensee signing fee and patent costs reimbursement usd [ * * * * ] ; payment due within 60 days after signing of license agreement. all current and future patent costs will be paid by licensee in countries chosen by licensee. payments when reaching certain development steps ( milestone